The Legal Cannabis Market Gaining Global Attention

Wednesday, March 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 29, 2017 /PRNewswire/ -- News Commentary 

Data published in a research

report by Grand View Research, Inc., projects that the global medical cannabis market will reach a value of USD 55.8 billion by 2025. The projection takes into consideration the continuous successful legalization campaigns
in the United States and a more open approach towards cannabis products around the world. In 2016, states - Arkansas, Florida, North Dakota, Ohio, and Pennsylvania legalized cannabis products for medical purposes, such as chemotherapies and pain management. CURE Pharmaceutical Holding Corp. (OTC: CURR), Earth Science Tech Inc. (OTC: ETST), General Cannabis (OTC: CANN), General Cannabis (OTC: CANN), OWC Pharmaceutical Research Corporation (OTC: OWCP), Cannabis Sativa Inc. (OTC: CBDS).

The research indicates that there is an increasing interest amongst academic researchers and healthcare providers regarding the therapeutic potential of cannabis products. Some of the potential therapeutic values are suppression of vomiting & nausea, pain relief and appetite stimulation. In addition, cannabis is effective in providing relief to the patient suffering from HIV/AIDS, glaucoma, cancer and multiple sclerosis. In the year 2015, chronic pain was the largest application segment in this market.

CURE Pharmaceutical Holding Corp. (OTCQB: CURR) is a drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs).

Earlier today, CURE Pharmaceutical Holding Corp. announced a distribution and license agreement with Long Beach, Calif-based, Redbarn Pet Products, LLC ("Redbarn"), for the development of various oral thin film veterinary products. The demand for US animal health products is more than $12 billion per year.

"This agreement is important for CURE as it marks the first distribution and licensing agreement we have executed since we received our method of use for animal products. We are grateful and excited to be working with such a high quality partner and look forward to a long-standing relationship with Redbarn," said Rob Davidson, CEO of CURE Pharmaceutical. "Further, it demonstrates the versatility of our CureFilm™ technology, allowing it to easily be applied to both human and animal consumption, as well as both OTC and Rx formulation. We anticipate multiple additional deals to be announced in the short term, and look forward to sharing these milestones with our stockholders."

As part of the agreement, CURE will formulate, develop and manufacture a variety of pet products, including multi-vitamins; flea, tick, heartworm, weight control, joint care, dental, shin health, digestive health, behavioral relief, anal glad and antifungal; hip and joint; allergies, pain and anti-nausea products to be sold over-the-counter. CURE will also provide Redbarn with products for dogs and cats specifically distributed through veterinary offices, including anti-inflammatory, pain relief, itch relief, allergies, anti-nausea, blood pressure or fluid retention, epilepsy and seizure control; heart, antibiotics and steroids.  All of these products will utilize the company's proprietary formulation and manufacturing capabilities and its patented CureFilm™ technology.

Earth Science Tech Inc. (OTC: ETST), an innovative biotech company focused on industrial hemp and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its two subsidiaries: Earth Science Pharmaceutical and Cannabis Therapeutics, announced the projected timeline for the delivery of its MSN-2 medical device, the negotiation of a strategic partnership with Connexions Commerciales Internationales CT Inc., and the beginning of negotiations with partners in Africa and Japan. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties.

General Cannabis (OTCQB: CANN), the comprehensive resource for the highest quality service providers available to the regulated Cannabis Industry, announced today that its security division, Iron Protection Group (IPG), the premier provider of protection services for the regulated cannabis industry, will begin offering its services in California. By opening an office in Sacramento, IPG will serve the largest regulated cannabis market in the world, now that the state voted to legalize the recreational use of marijuana for adults last November. "The demand for security services in California is skyrocketing," said Hunter Garth, Managing Director of IPG. "As a known security leader in Colorado, we are now seeing a dramatic rise in security and transportation requests from companies throughout the state. By opening our first office in the state capital, we plan to fulfill a vital component of the regulated cannabis industry in this substantial market."

OWC Pharmaceutical Research Corporation (OTCQB: OWCP), through its wholly-owned subsidiary, One World Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. The company announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis. Chairman and CEO, Mr. Mordechai Bignitz, has directed OWC's scientific team to submit an operating plan within 60 to 90 days to conduct double-blind efficacy tests of our cannabinoid-based topical cream on other skin disorders and conditions. Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs, commented, "As a practicing physician and a scientist who has been treating patients with cannabis for medical purposes for more than two decades, I am truly excited by our success to date and, more importantly, I am thrilled to be part of a professional scientific study on humans that should actually validate what I have believed and experienced for years - Cannabis helps treat a multitude of health conditions."

Cannabis Sativa Inc. (OTCQB: CBDS) develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula. The Company is also developing a third strain of cannabis plant named CT22. The Company also conducts its operations through its subsidiary; Wild Earth Naturals Inc. Wild Earth is an herbal skin care products formulation and marketing company that plans to target the natural healthcare products market in the United States and abroad. It offers Go Deep, Go Deep EXTRA, Face Garden, Body Garden and Lip Garden.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated four thousand dollars for financial news dissemination and pr services by a third party non affiliate for cure pharmaceutical holding corp. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: +1-877-601-1879




Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store